Roche has launched a global cancer immunotherapy Centers of Research Excellence network, saying it will invest up to 100 million Swiss francs ($100.3 million) in the project.
If heredity puts you at higher risk for a heart attack, maintaining a healthy lifestyle can bring that risk down dramatically – below the risk faced by some people whose genes would normally protect them from heart disease – according to a new analysis of more than 55,000 people.
Doctors in the Netherlands say they have successfully tested an implantable computer-brain interface that allowed the mind of a “locked-in” patient to spell messages at the rate of two letters per minute.
The U.S. Food and Drug Administration rejected Dynavax Technologies Corp.’s hepatitis B vaccine for the second time in three years.
Signals from Swiss drugmaker Novartis that it could unload its struggling Alcon eyecare business is the latest step in dismantling former leader Dan Vasella’s vision of building a European healthcare giant.
Corbus Pharmaceuticals Holdings Inc. said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis.
With Bristol-Myers Squibb, Genentech and Merck & Co. Expanding in the Bay Area, Some Wonder if the Real Estate Boom is Too Much
Biotech construction in the San Francisco Bay Area is booming, as it is in Boston. Merck may have a deal for 300,000 square feet in South San Francisco. Genentech, part of the Roche Group, acquired four buildings it had been leasing and is potentially acquiring four more.
Celgene executive Rich Bagger will return to the private sector. That was the message President-elect Donald Trump’s transition team told the New York Times.
U.S. pharmaceuticals giant Pfizer is to offer its pneumococcal vaccine at the lowest possible price to non-governmental organizations seeking to protect vulnerable people from illness in humanitarian crises.